Kwality Pharmaceuticals Deep Dive | 1000 Crore Roadmap | Episode 4|

Описание: Timestamps
00:00 Context pharma and CDMO space
00:36 Historical financial trajectory
01:40 Past execution track record against targets
02:04 Long term roadmap to FY29
04:22 Transition to high barrier complex formulations
04:54 Mechanics of out licensing versus in licensing models
05:53 CDMO contract manufacturing and formulation modification analogy
09:03 Export market split and geographic mix
10:35 Overview of the six production facilities
11:40 Breakdown of general therapeutics and oncology assets
13:34 Next generation biologics and hormone block pipelines
17:54 Capex mismatch against operating cash flows
18:23 Stretched working capital cycle and maritime transit lags
20:18 Long term product mix evolution toward complex peptides
22:57 Granular top line and bottom line guidance for FY27
24:19 Regulatory filings as a proxy for forward growth
25:06 Factory utilization rates and quality control frameworks
26:44 Advanced formulation delivery systems
27:52 Retaining currency gains as a macro raw material hedge
30:02 Analysis of short term gross margin compression
31:54 Operational comparison against Solara Active Sciences
33:15 Risk summary covering regulatory friction and governance upgrades
35:06 Expectation management warning of a flat H1 FY27
36:11 Forward valuation summary and closing notes